Literature DB >> 30150129

Quality of life in long-term botulinum toxin treatment of cervical dystonia: Results of a cross sectional study.

Marek Moll1, Dietmar Rosenthal1, Harald Hefter2.   

Abstract

INTRODUCTION: Patients' rating of the effectiveness of and quality of life after long-term botulinum toxin (BoNT) injection therapy up to 22 years and treating physician's rating of the therapy effect in patients with idiopathic cervical dystonia (CD) are analysed in a large monocentric cross-sectional study. PATIENTS AND METHODS: Patients (n = 221) who received uninterrupted, long-term treatment for CD (≥10 BoNT injection cycles) in a BoNT outpatient clinic underwent detailed clinical investigation, Tsui scoring, rated post-treatment CD severity as a percentage of CD severity prior to BoNT injection (patient's subjective scoring of the treatment effect (PSSTE)), and completed the CDQ-24 quality of life (QoL) questionnaire. Correlations between demographics, treatment-related data and QoL were analysed by linear regression, analysis of variance and pairwise single comparisons.
RESULTS: Treating physicians and patients rated mean ongoing treatment effect as >50%. There was high variability of duration of treatment, PSSTE, Tsui score and CDQ-24 across all patients. PSSTE was significantly correlated with Tsui score (p < .001) and all CDQ-24 subscores (p < .003). Tsui score and CDQ-24 were significantly correlated (p < .001), but the correlation was lower than between PSSTE and total CDQ24. CDQ-24 revealed a significant improvement with duration of therapy. PSSTE and Tsui score did not change with duration of BoNT treatment.
CONCLUSION: Patients with CD who receive up to 22 years' continuous BoNT treatment experience a >50% mean reduction of symptoms and a significant improvement of QoL with duration of treatment. A highly significant correlation exists between patients' and physicians' rating of treatment effectiveness.
Copyright © 2018. Published by Elsevier Ltd.

Entities:  

Keywords:  Botulinum toxin therapy; Cervical dystonia; Effectiveness of BoNT therapy; Long-term treatment; Quality of life

Mesh:

Substances:

Year:  2018        PMID: 30150129     DOI: 10.1016/j.parkreldis.2018.07.019

Source DB:  PubMed          Journal:  Parkinsonism Relat Disord        ISSN: 1353-8020            Impact factor:   4.891


  10 in total

1.  Efficacy and safety of long-term botulinum toxin treatment for acquired cervical dystonia: a 25-year follow-up.

Authors:  Martina Petracca; Maria Rita Lo Monaco; Tamara Ialongo; Enrico Di Stasio; Maria Luana Cerbarano; Loredana Maggi; Alessandro De Biase; Giulia Di Lazzaro; Paolo Calabresi; Anna Rita Bentivoglio
Journal:  J Neurol       Date:  2022-09-06       Impact factor: 6.682

2.  Needs and Perceptions of Patients With Dystonia During the COVID-19 Pandemic: A Qualitative Framework Analysis of Survey Responses From Italy.

Authors:  Vittorio Rispoli; Matías Eduardo Díaz Crescitelli; Francesco Cavallieri; Francesca Antonelli; Stefano Meletti; Luca Ghirotto; Franco Valzania
Journal:  Front Neurol       Date:  2022-06-16       Impact factor: 4.086

3.  Disease Progression of Idiopathic Cervical Dystonia in Spite of Improvement After Botulinum Toxin Therapy.

Authors:  Harald Hefter; Isabelle Schomaecker; Max Schomaecker; Sara Samadzadeh
Journal:  Front Neurol       Date:  2020-11-12       Impact factor: 4.003

4.  Internet-based cognitive behavioural therapy as a feasible treatment of adult-onset, focal, isolated, idiopathic cervical dystonia.

Authors:  Megan E Wadon; Claire MacIver; Mia Winter; Kathryn J Peall
Journal:  Clin Park Relat Disord       Date:  2021-11-27

5.  Adult-onset idiopathic dystonia: A national data-linkage study to determine epidemiological, social deprivation, and mortality characteristics.

Authors:  Grace A Bailey; Anna Rawlings; Fatemeh Torabi; Owen Pickrell; Kathryn J Peall
Journal:  Eur J Neurol       Date:  2021-10-15       Impact factor: 6.288

6.  The complex relationship between antibody titers and clinical outcome in botulinum toxin type A long-term treated patients with cervical dystonia.

Authors:  John-Ih Lee; Philipp Albrecht; Sara Samadzadeh; Harald Hefter; Beyza Ürer; Raphaela Brauns; Dietmar Rosenthal; Sven G Meuth
Journal:  J Neurol       Date:  2022-07-17       Impact factor: 6.682

7.  Clinical relevance of neutralizing antibodies in botulinum toxin long-term treated still-responding patients with cervical dystonia.

Authors:  Harald Hefter; Dietmar Rosenthal; Hans Bigalke; Marek Moll
Journal:  Ther Adv Neurol Disord       Date:  2019-12-16       Impact factor: 6.570

8.  Significant Long-Lasting Improvement after Switch to Incobotulinum Toxin in Cervical Dystonia Patients with Secondary Treatment Failure.

Authors:  Harald Hefter; Beyza Ürer; Raphaela Brauns; Dietmar Rosenthal; Sven G Meuth; John-Ih Lee; Philipp Albrecht; Sara Samadzadeh
Journal:  Toxins (Basel)       Date:  2022-01-06       Impact factor: 4.546

9.  The Use of High Initial Doses of Botulinum Toxin Therapy for Cervical Dystonia Is a Risk Factor for Neutralizing Antibody Formation-A Monocentric Cross-Sectional Pilot Study.

Authors:  Harald Hefter; Isabelle Schomaecker; Max Schomaecker; Dietmar Rosenthal; Sara Samadzadeh
Journal:  Medicina (Kaunas)       Date:  2022-01-07       Impact factor: 2.430

10.  The Impact of the Course of Disease before Botulinum Toxin Therapy on the Course of Treatment and Long-Term Outcome in Cervical Dystonia.

Authors:  Harald Hefter; Isabelle Schomaecker; Max Schomaecker; Dietmar Rosenthal; Sara Samadzadeh
Journal:  Toxins (Basel)       Date:  2021-07-16       Impact factor: 4.546

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.